Cigarette smoking is more prevalent in subjects with schizophrenia compared to those with other psychiatric disorders or the general population and could therefore affect molecular pathways that impact the pathophysiology of this disorder. As smoking is also known to suppress immune responses, we investigated the effects of 'smoking-conditioned' serum obtained from schizophrenia and control subjects on healthy T cell in vitro. We found that T-cell proliferation was significantly increased following exposure to serum from smoking schizophrenia patients whereas no effect was observed when using serum from smoking control subjects or non-smoking patients and controls. We eliminated the possibility that these effects were due to quantitative differences in cigarette consumption as serum levels of the stable nicotine metabolite cotinine were similar in schizophrenic and control smokers. Molecular characterization showed that serum from patient smokers increased expression of T-cell activation markers CD69 high , CD25 high , co-stimulatory molecules CD26 þ , CD27 þ and CD28 þ , and decreased T-cell receptor complex components TCRa/b and CD3. Moreover, analysis of supernatants collected after T-cell exposure to serum from smoking patients showed a time-dependent decline in interleukin (IL)-2 levels, suggesting that the proliferation effect is promoted by enhanced IL-2 processing. These results suggest that cigarette smoking has selective effects on serum components that, in turn, lead to altered immune function in schizophrenia patients relative to healthy subjects. Further studies aimed at characterizing these components could result in a better understanding of the onset and aetiology of schizophrenia and potentially lead to novel therapeutic strategies.
Introduction
Compared to the general population and other psychiatric disorders, cigarette consumption is highest among schizophrenia patients. 1, 2 Their dependence on nicotine is approximately three times that of the general population with a prevalence reaching almost 90%. 3 Investigations of smoking behaviour among schizophrenia patients have shown that they smoke more, exhibit stronger addictive behaviours and encounter more difficulties with smoking cessation compared to healthy cigarette consumers. 4, 5 Patients may use cigarettes as a form of self-medication, 6 as a consequence of the stimulatory effect of nicotine on the mesolimbic dopamine system that improves positive and negative symptoms as well as cognitive functions such as memory and attention. 7, 8 However, cigarette smoking is a well-known risk factor of cardiovascular and respiratory disease. 9 Schizophrenia patients have a reduced life expectancy of approximately 20% compared to the general population with coronary heart disease accounting for about two-thirds of the mortality rate. 10 This disease susceptibility may be exacerbated through the suppressive effect of cigarette smoking on the immune system. 11, 12 Nicotine, the major active chemical in cigarettes, has been shown to impair antigen-driven T-cell response and inhibit proliferation in rodents as well as humans. [13] [14] [15] [16] T lymphocytes have integral function in cell-mediated immunity and are involved in host defence against infectious agents. Peripheral changes in the immune system of schizophrenia patients, such as decreased cellular immune response 17, 18 and altered cytokineexpression, 19 have been reported. However, these immunological findings are inconsistent and controversial due to different methodological approaches, the heterogeneity of sample sourcing and acquisition, as well as lack of controls for confounding factors such as smoking. 20 To investigate whether smoking has a distinct effect on the molecular pathways associated with the immune response in schizophrenia, we examined the functional response of normal T cells in vitro to serum obtained from first-onset anti-psychotic naive patients and healthy controls (HCs). The main objective was to determine whether cell-extrinsic serum factors from schizophrenia smokers evoke distinct disease-associated differential T-cell responses.
Materials and methods

Sample collection
Subjects for T-cell isolation. CD3 þ pan T cells were isolated from peripheral blood from healthy volunteers recruited at the University of Cambridge showing no comorbidities such as diabetes, heart disease, thyroid disease, autoimmune disease or any recent infections. Volunteers with a psychotic family history or drug abuse were also excluded. All subjects gave written consent.
Subjects for serum collection. The study was approved by the local ethics committee and subsequently performed at the University Hospital of Cologne. All patients and healthy volunteers gave their written informed consent. We consecutively recruited 24 subjects, comprising 12 HCs with no family history of schizophrenia or detectable medical, psychiatric or neurological history and 12 patients suffering from first-episode paranoid psychosis (Table 1 ). All patients were drug naive for antipsychotic medication. HCs were matched for age, gender, smoking and ethnicity. None of the HCs developed schizophrenic symptoms during the follow-up period of at least 1 year. HCs were carefully screened for medical disorders (such as diabetes, heart disease, thyroid disease, autoimmune disease or any recent infections) and current or previous psychiatric illnesses using the severe combined immunodeficiency for Diagnostic and Statistical Manual of Mental Disorders, fourth edition; no previous or current diagnosis of illicit drug abuse or dependence and no cannabis use within the past 6 months before the study were allowed. Psychopathology of the patients was assessed on the day of the blood withdrawal and measured by using the Positive and Negative Syndrome Scale (PANSS) rating scale (PANSS total: 100.7 ( ± 24.0), positive symptoms: 25.4 ( ± 4.6), negative symptoms: 22.7 ( ± 8.8), general symptoms: 52.6 (±11.6)). Serum samples were produced by allowing blood to coagulate for 2 h at room temperature, centrifuged at 4000 g, 5 min and the supernatant was collected. Samples were stored at À80 1C until use.
T-cell isolation and stimulation
Peripheral blood was collected from consenting participants into 9 ml EDTA S Monovette tubes (Sarstedt). PBMCs (peripheral blood mononuclear cells) were isolated by centrifugation over FicollPaque Plus (GE Healthcare) and washed in Dulbecco's phosphate-buffered saline (DPBS; Invitrogen, Paisley, Renfrewshire, UK). T cells were obtained by negative selection using the MACS human pan T-cell isolation kit II in association with LS MACS separation columns (Miltenyi Biotech, UK) according to the manufacturer's specifications. T-cell purity (routinely above 95%) was assessed by flow cytometry (CyAn; DakoCytomation, UK) measuring expression of the T-cell marker CD3-e. CD3 þ T cells from healthy donors were cultured in triplicate in RPMI 1640 medium (Sigma, Poole, Dorset, UK) supplemented with 1% glutamine, penicillin, streptomycin (referred to as incomplete medium) in the absence or presence of 1 mg ml À1 anti-CD3 (clone OKT3). Serum (10%) from a panel of schizophrenia patients and matched controls was added to each well before incubation at 37 1C, 5% CO 2 for 48 h. Cells were pulsed with 0.037 MBq 3 H-thymidine (Amersham Biosciences, Little Chalfont, Bucks, UK) allowing incorporation into DNA for a further 24 h incubation and DNA harvested onto 96-well filter plates (PerkinElmer, Seer Green, Bucks, UK). T-cell proliferation was determined by measuring the incorporation of 3 H-thymidine into progeny DNA using a liquid scintillation counter (Packard, Isotech, Chesterfield, Derbe, UK). The intra-and inter-assay variability was < 15% coefficient of variation (CV).
T-cell surface marker analysis
To corroborate the difference in proliferation between the patient and control smokers we treated T cells Cytomation) to ensure accurate and uniform parameters. The inter-assay variability was < 15% CV. Lymphocytes were gated on CD3 þ T cells and 10 000 events were recorded. Data were processed and analysed with FlowJo software 7.2.2 for Windows (Tree Star, Ashland, OR, USA). The expression of cellsurface markers was calculated as median fluorescence intensity (FI) to determine cell-surface antigen density and frequency (%) of antigen presentation for CD4 þ and CD8 þ T-cell-distinct positive and negative subpopulations. For single populations (% = 100), the median FI was taken into account.
Cytokine analysis
Supernatants from T cells (n = 15) stimulated with anti-CD3 in the presence of patient (n = 3) or controlsmoker serum (n = 3) were collected after 0, 24 and 48 h of culture, centrifuged and stored at À80 1C before use. The cytokines interleukin (IL)-2, IL-10 and INF-g were quantified by commercially available enzyme-linked immunosorbent assays (ELISA; eBioscience) according to the manufacture's specifications. All ELISAs were specific for the relative cytokine and inter-and intra-assay variation was less than 10% CV in each case. In brief, T-cell supernatants were diluted 1:2 in dilution buffer and added together with 100 ml of each standard diluent to the plate. This was incubated at 4 1C overnight to achieve maximal sensitivity. Plates were washed 5 Â in assay diluent and subsequently incubated with detection antibody, avidin-horseradish peroxidase and substrate solution according to the manufacturer's protocol. The reaction was terminated with 50 ml stop solution and results were quantified at 450 nm using a plate reader (Bio-Rad, Birmingham, Warks, UK).
Cotinine analysis
Cotinine serum levels of 12 patient and 12 control samples were quantified by direct ELISA (Calbiotech, Spring Valley, CA, USA) following the manufacturer's protocol. The inter-and intra-assay variation was < 15% CV for standard and < 20% CV for the analysed samples. In brief, 10 ml of serum and cotinine standard was added in duplicate to each well and incubated with 100 ml cotinine enzyme conjugate for 1 h at room temperature. Wells were washed with distilled water before addition of 100 ml TMB substrate solution. This was incubated for 30 min at room temperature before reaction was stopped with stop solution. Plates were read at dual wavelengths of 450 and 650 nm on a plate reader (Bio-Rad).
Statistical analysis
Data were analysed in GraphPad Prism (La Jolla, CA, USA). Statistical analyses for the cell-surface marker expression and cytokine ELISA studies were performed using Wilcoxon matched pair's test. P-values of less than 0.05 were considered significant. Using the same method, statistical significance was calculated for proliferation study 1 and 2 independently. Pearson's correlation coefficients were determined to investigate the effect of age, gender, smoking and cotinine concentrations on proliferative responses. Using the same method, the correlation between cotinine concentrations and the quantity of cigarettes smoked per day was assessed. Statistical significance of the cotinine ELISA study was determined by nonparametric Mann-Whitney U-test. P-values of less than 0.05 were considered significant.
Results
Effect of patient serum on T-cell proliferation
The proliferative effects of patient and control serum on normal T cells incubated in the presence or absence of anti-CD3 were determined by 3 H-thymidine incorporation. Because the number of serum samples per experiment was limited by the amount of T cells obtained from a single donor, proliferation measurements were divided over two separate studies as indicated in Table 1 . Both studies were performed under identical conditions; however, different serum and T-cell sample cohorts were investigated in each study, thus the second validates findings obtained in the first study. We found a significant correlation between smoking and proliferation (P < 0.03) that was independent of the smoking status of healthy T-cell donors (P = 0.3) and of age or gender. Serum from schizophrenia smokers induced a 1.2-fold (study 1) and 1.4-fold (study 2) higher response compared to serum from HC smokers ( Figure 1a ) and a similar 1.2-fold (study 1) and 1.5-fold (study 2) increase compared to serum from schizophrenic non-smokers (Figure 1c) . No difference in proliferation was found between non-smokers regardless of health status (Figure 1b ) nor between HC smokers and non-smokers (Figure 1d) , suggesting that the altered proliferative 
Measurement of serum cotinine levels
We measured cotinine levels in serum samples to determine if the differential effect in proliferation was associated with the rate of smoking. Cotinine, the major nicotine metabolite, was chosen as the most reliable indicator of nicotine levels as it resides in the blood stream between 15 and 17 h compared with only 2 and 4 h for nicotine. 21, 22 Serum cotinine concentrations correlated strongly with the selfreported number of cigarettes smoked per day in patients (R 2 = 0.59) as well as HCs (R 2 = 0.69). However, no significant differences in cotinine levels were found between healthy and patient smokers and cotinine concentrations did not correlate with the proliferative responses in either the patient (R 2 = 0.00) or control (R 2 = 0.02) group (data not shown).
Effects on cell-surface marker expression For further molecular characterization of the T-cell activation response, we measured expression levels of various T-cell surface markers using four-colour staining. This was determined as the median FI and frequency (%) for cases in which distinct positive (for example, CD69 high ) and negative (for example, CD69 low ) populations were present. In cases where population frequencies were 100% (for example, CD26 þ ), only the median FI was taken into consideration. All antigens were examined for unstimulated and stimulated CD4 þ and CD8 þ subpopulations. No differences between the two groups were found for CD4 þ and CD8 þ single populations or CD4 þ /CD8 þ ratios (data not shown).
Patient serum effects on T-cell receptor complex molecules
The T-cell proliferative response to antigen recognition is tightly regulated by CD3 and by degradation and downregulation of the T-cell receptor (TCR) complex TCRa/b. 23 After stimulation, the median FI of the TCRa/b receptor was decreased 1.4-fold following patient serum exposure from smokers in CD4 þ cells (P < 0.005) and 1.3-fold in CD8 þ cells (P < 0.02), compared with the effects seen after exposure to control serum from smokers (Table 2 ). In addition, the CD3 antigen was decreased 1.2-fold following treatment with patient serum in CD4 þ cells compared to controls (P < 0.007). No difference was observed in CD8 þ cells.
Patient serum effects on co-stimulatory molecules T-cell activation was also evaluated by measuring the expression of co-stimulatory molecules: CD26, a dipeptidyl peptidase IV cell-surface protease; CD27, a member of the tumour necrosis factor (TNF) receptor family and CD28, a member of the B7 costimulatory family. [24] [25] [26] All receptors showed significant upregulation in response to patient serum exposure from smokers in stimulated CD4 þ and CD8 þ cells compared to the effects seen with control serum from smokers (CD4 þ CD26 þ , 1.2-fold; Table 2) . Figure 1 The effect of patient and control serum on T-cell proliferation. Plotted are the pair-wise comparisons of T-cell proliferative responses following exposure to (a) serum from healthy control (C) or schizophrenia (P) smokers (S), (b) serum from healthy control and patient non-smokers (NS), (c) serum from non-smoking and smoking patients and (d) serum from non-smoking and smoking controls. Both studies were performed under identical conditions at different time points using independent serum and T-cell sample cohorts (study 1, n = 18; study 2, n = 11). # of sera, the number of serum samples averaged per T-cell donor for each indicated group; FC, fold change; **P < 0.005, ***P < 0.0005.
Patient serum effects on T-cell activation T-cell activation through antigen stimulation evokes upregulation of distinct activation markers. We analysed the expression of the early and late activation markers CD25 and CD69 on CD4 þ and CD8 þ cells ( Table 2) . Expression of CD69 high and CD25 high is characteristic of activated cells whereas CD69 low and CD25 low expression is usually associated with quiescent cells. The frequency and median FI of CD4 þ CD69 high (%, P < 0.003; FI, P < 0.0005) and CD8 þ CD69 high (%, P < 0.01; FI, P < 0.003) phenotypes were significantly augmented in stimulated T cells after exposure to patient serum from smokers compared to that from control smokers (Figure 2) . Consistent with this, the expression pattern of the CD69 low population showed decreased FI and frequency on CD4 þ (FI, P < 0.0005; %, P < 0.005) and CD8 þ (FI, P < 0.03; %, P < 0.002) cells after treatment with patient serum from smokers. In addition, the frequency of CD4 þ and CD8 þ cells expressing CD25 high (IL-2 receptor a-chain) was significantly enhanced by treatment with patient serum from high on CD4 þ and CD8 þ cells. *P < 0.05, **P < 0.005, ***P < 0.0005. Table 2 ).
Measurement of IL-2 concentration in T-cell supernatants T cells respond to TCR stimulation by the production of cytokines. To investigate whether serum from schizophrenia smokers induced a proinflammatory or anti-inflammatory skewed T-cell response, we analysed their ability to produce interferon-g (IFN-g) and IL-10 cytokines. We also measured concentrations of IL-2, a cytokine produced at an early stage by T cells in response to antigen stimulation. Once secreted, IL-2 binds to CD25 to promote T-cell proliferation. 27 There were no differences in IL-10 and IFN-g concentrations in T-cell supernatants (data not shown). Also, no difference in IL-2 concentration was found in unstimulated cells or cells that had been stimulated for 24 h. However, IL-2 levels were decreased 1.3-fold (P < 0.006) following exposure to serum from schizophrenia smokers compared to control smokers after 48 h treatment (Figure 3 ).
Discussion
The association between smoking and schizophrenia has been highlighted on previous occasions. 28, 29 Most reports have commented on the socio-economic and behavioural issues of cigarette consumption in chronically ill and anti-psychotic-treated patients. However, increased tobacco consumption is apparent in the early and prodromal stages of schizophrenia. 30 Furthermore, a positive relationship was found between smoking status and level of schizotypy, where higher levels of schizotypy significantly predicted the risk of being a smoker after controlling for gender and group status. 31 Heavy smoking in patients has been regarded as an attempt of self-medication and there is evidence that nicotinic agonists improve clinical ratings of negative symptoms that are generally resistant to treatment with dopamine antagonist anti-psychotic drugs. 32 This implies that cigarette compounds may activate compensatory or beneficial mechanisms ameliorating the pathophysiology of the disease.
In the current study, we have shown that T cells from healthy donors undergo increased proliferation following exposure to serum from drug-naive, firstonset schizophrenia smokers. This effect was not observed after exposure to serum from control smokers or from schizophrenia non-smokers. Interestingly, it is documented that chronic exposure to cigarette compounds such as nicotine suppresses immune functions including T-cell proliferation. 33, 34 A study by Frazer-Abel et al. 15 showed that direct addition of nicotine to T cells in vitro decreases their proliferation by prevention of cell-cycle entry in G 0 -G 1 transition. However, the present results imply that smoking exerts differential effects in patients leading to altered T-cell proliferation and that these effects are disease associated rather than related to smoking as no proliferative difference was observed between healthy smokers and non-smokers. In addition, preliminary crossover experiments from our laboratory show that T cells from schizophrenia patients show decreased proliferation only after exposure to serum from schizophrenia smokers (unpublished data). Substances produced from tobacco smoke may therefore interact differently with key regulatory factors circulating in patient serum but not in serum from normal subjects. The presence of these factors, rather than components of cigarette smoke, could have affected the observed difference in proliferation even though nicotine and cotinine are known to trigger cholinergic anti-inflammatory pathways and proliferation in non-excitable cells through activation of the a7 subtype of the nAChR (a7nAChR). [35] [36] [37] One previous study showed decreased levels of a7nAChR mRNA in peripheral blood lymphocytes from schizophrenia patients and the authors ruled out the possibility that this resulted from nicotine consumption as there was no difference between HC smokers and non-smokers. 38 However, they did not investigate whether there was any effect of smoking on a7nAChR expression within the schizophrenia patient group, a possibility that should be considered in the light of the results of the present study.
T-cell activation is a complex process involving a panoply of tightly regulated, dynamic events resulting in the expression of cell-surface marker molecules that in turn control T-cell function and proliferation. 39, 40 We demonstrated that increased proliferative response of exogenous T cells exposed to sera from smoking schizophrenia patients was also associated with increased expression of the activation markers CD69 high and CD25 high and co-stimulatory molecules CD26 þ , CD27 þ and CD28 þ , along with downregulation of the TCR complexes CD3 þ and TCRa/b. These findings suggest that, in vivo, T cells from schizophrenia patients are activated in response to unidentified circulating factors associated with cigarette smoking. Long-term activation could then lead to desensitization of the proliferation responses as indicated by a reduced proliferative rate of schizophrenia patient-derived T cells, implying that patient T cells have become refractory to stimulation and respond significantly less to in vitro stimulation. 17, 18, 41 T-cell activation in the patient's body, as shown here through elevated levels of CD25 high and CD69 high , could furthermore help to recruit T cells to cross the blood-brain barrier to foster communication between the central nervous system and the immune system. Previous studies have shown that T cells have beneficial effects on a damaged central nervous system. 42, 43 Smoking may therefore be an attempt to enhance the deficient immune response in schizophrenia patients to maintain brain homoeostasis.
We also found an increased expression of the IL-2 receptor a-chain (CD25) and a time-dependent decline in IL-2 concentration in T-cell supernatants after treatment with serum from schizophrenic smokers. Once secreted, IL-2 works as an autocrine factor by binding to CD25, promoting proliferation and survival of recently activated T cells such as CD25 þ regulatory T cells. Interestingly, IL-2 concentrations were comparable between the patient and control smoking groups demonstrating that cells were equally able to produce IL-2 after 24 h of stimulation. This suggests that the observed decline in IL-2 levels in the patient smoker group after 48 h is most likely due to enhanced processing of IL-2 potentially by increased levels of CD25 receptors. This result further supports the possibility that proliferation of T cells following exposure to patient serum from smokers is driven by enhanced IL-2 signalling.
The most intriguing finding of the current study was the observed increase in T-cell proliferation after exposure to serum from schizophrenic smokers. We have demonstrated that this effect was not due to differences in nicotine metabolism as cotinine levels were not significantly different in the sera of schizophrenic and control smokers. We also excluded the possibility that the effect was due to alterations in the inflammatory response by showing that the concentrations of IL-10 and IFN-g in serum from schizophrenic and HC smokers were comparable. One advantage of the present study comes from the use of samples from drug-naive, first-onset patients, thereby ruling out the potentially confounding factor of drug treatment and, most importantly, allowing for investigation of disease-related pathologies at an early stage of illness. In this case a given abnormality might represent a primary disease-associated pathology rather than one that has arisen as a consequence of long-term disability, social deprivation or drug treatment.
Considering the complexity of the serum proteome, and the fact that tobacco smoke contains more than 4000 chemicals besides nicotine, there is considerable scope for future studies to characterize the molecular pathways involved in T-cell function. The molecular sequela linked to the presence of confounding factors such as smoking is still poorly understood. Our preliminary findings point towards the existence of smoking-related molecular pathways underlying the disorder, which could open new avenues for biomarker discovery strategies. The results also emphasize the importance of considering confounding factors such as substance abuse to avoid difficulties in assessing disease-relevant alterations. The combined application of functional cell studies and multi-tiered profiling experiments should have great potential to elucidate the physiological systems involved in the onset and aetiology of schizophrenia and could lead to the discovery of biomarker candidates with therapeutic potential. Much of the recent work undertaken within our laboratory has focused on proteomic profiling of cerebro spinal fluid and serum from schizophrenia patients at various stages of disease. We have found a number of significantly altered proteins and peptides that may be involved in or are linked to the current findings. 44, 45 Taken together, these results show that T cells from healthy donors respond differently to serum from patient smokers compared to control smokers. Despite similar cotinine concentrations in serum, this physiological difference is reflected in disturbed T-cell function including upregulation of activation markers and increased IL-2 processing. This suggests that sera from schizophrenia patients contain one or more factors that, in combination with specific products of tobacco smoking, can lead to an altered immune response. Identification and characterization of these components in the context of these findings could lead to the discovery of novel biomarkers for early diagnosis and new therapeutic strategies.
